Navigation Links
Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
Date:6/2/2008

- 50% of All Evaluable Patients in Phase I Study Receiving Combination of Bavituximab Plus Chemotherapy Achieved Objective Tumor Response or Stable

Disease - - 100% of Evaluable Patients to Date in Ongoing Phase II Breast Cancer

Study Showing Objective Tumor Response or Stable Disease -

CHICAGO and TUSTIN, Calif., June 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase I data indicated that half of evaluable patients in the trial achieved objective tumor response or stable disease after eight weeks of dosing. The Phase I study results also showed that the safety profile of bavituximab and chemotherapy appeared consistent with chemotherapy alone and that the pharmacokinetic properties of bavituximab were not impacted by co- administration with conventional chemotherapies.

Separately, Peregrine reported an update from its ongoing Phase II trial evaluating bavituximab plus docetaxel in advanced breast cancer. Enrollment of an initial group of 15 patients in the two-stage Phase II study was recently completed. Of the 11 evaluable patients to date, none have experienced any measureable tumor growth or disease progression, with five of the 11 evaluable patients achieving a partial tumor response. All enrolled patients are continuing to receive treatment and are being evaluated regularly for tumor response according to RECIST criteria. The primary objective of the multi-center, open
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
2. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
9. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
10. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
11. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Boston, MA (PRWEB) January 22, 2015 ... systems, is pleased to announce an exciting product from a ... of motion analysis solutions over the past 15 years, with ... industries. Most recently, their 3D IMU system (inertial measurement unit), ...
(Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
(Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... libraries with high-titer efficiency and larger insert,potential ... cDNA Expression Libraries , Katherine Felts ... ,Anna Waesche Peter Vaillancourt ,Stratagene , ... expression libraries inserted into the,high-titer retroviral vector ...
... High-quality plasmid DNA for all demanding molecular ... Jeff Braman ,Stratagene , A new technique ... reliably isolate,high-purity plasmid DNA. The convenient spin-format ... columns, and alcohol precipitations, while,easily accommodating simultaneous ...
... RT-PCR systems excel at amplifying challenging targets ... Hogrefe ,Stratagene , We compared Stratagenes prostar RT-PCR ... see how well they performed.,The ProSTAR HF single-tube ... ,Precision DNA polymerase blend * and a convenient ...
Cached Biology Technology:Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 2Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 3Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 4Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 5Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 6Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 7Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 8Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 9Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 10Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 11A Simple and Rapid Technique to Purify High-Quality Midiprep DNA 2A Simple and Rapid Technique to Purify High-Quality Midiprep DNA 3A Simple and Rapid Technique to Purify High-Quality Midiprep DNA 4Performance Comparisons of Commercial RT-PCR Systems 2Performance Comparisons of Commercial RT-PCR Systems 3Performance Comparisons of Commercial RT-PCR Systems 4Performance Comparisons of Commercial RT-PCR Systems 5Performance Comparisons of Commercial RT-PCR Systems 6Performance Comparisons of Commercial RT-PCR Systems 7Performance Comparisons of Commercial RT-PCR Systems 8
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
(Date:1/22/2015)... DETROIT , Jan. 13, 2015 Technology Showcase, Hall ... iris-based identity authentication solutions, today announced it will showcase its ... and developed by the Department of Energy,s Oak Ridge ... International Auto Show . EyeLock,s iris identity authentication technology is ...
(Date:1/22/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a ... the recent success of the Wocket™ smart wallet at CES 2015 in ... was named as one of the "11 Hot Products at CES" in ... At CES So Far" by Newseveryday.com and "The top 10 gadgets from ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... research shows that in sub-Saharan Africa the virus responsible for ... and the African buffalo are important natural reservoirs for the ... open-access journal of the American Society for Microbiology, sheds light ... emerged in sub-Saharan Africa and identifies patterns of spread in ...
... suggests the southern portion of the Amazon rainforest is at ... drying than projections made by the climate models used in ... (IPCC). If severe enough, the loss of rainforest could cause ... dioxide into the atmosphere. It could also disrupt plant and ...
... A California walking stick insect that has evolved to ... camouflages well with broader leaves and a form with ... better with needle-like leavescan markedly affect its broader ecological ... with the plant it,s living on. The new ...
Cached Biology News:Foot and mouth disease in sub-Saharan Africa moves over short distances, wild buffalo are a problem 2Risk of Amazon rainforest dieback is higher than IPCC projects 2Risk of Amazon rainforest dieback is higher than IPCC projects 3Poorly camouflaged insects can kick off a cascade of ecological impacts, new CU-Boulder study finds 2Poorly camouflaged insects can kick off a cascade of ecological impacts, new CU-Boulder study finds 3
...
... APAgene kits are designed to rapidly ... using our patented APA Technology. APAgene provides ... competitive price. All necessary ingredients are provided ... can be used for gap filling, localized ...
N,N'-Methylene-bis-acrylamide, Ultra Pure...
... product is designed to deparaffinize and perform ... fixed paraffin-embedded tissue sections mounted on glass ... the paraffin at the high temperature used ... emulsification of the paraffin by detergent. Formaldehyde ...
Biology Products: